Health
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor
Today, AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (RINVOQ®) 15 mg, once daily, compared to adalimumab (HUMIRA®) 40 mg, every other week, in adult patients with moderate to severe rheumatoid arthritis (RA) on a stable background of methotrexate (MTX) who had an inadequate response or intolerance to a TNF inhibitor (TNFi) other than adalimumab.1 This study achieved the primary endpoi
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP ≤3.2) and ranked secondary endpoint of remission (DAS28-CRP <2.6) at week 121","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"SELECT-SWITCH is the first Phase 3b/4 head-to-head trial comparing TNF inhibitor cycling with switching to upadacitinib in adults with moderate to severe rheumatoid arthritis and inadequate response or intolerance to a TNF inhibitor1","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"The safety profile for upadacitinib was consistent with previously reported studies, with no new safety risks identified in the 12-week period1,2","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"The SELECT-SWITCH study results were recently published in Annals of the Rheumatic Diseases1.","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":673,"olType":false},{"type":"text","content":"MONTREAL, April 28, 2026 /CNW/ - Today, AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (RINVOQ®) 15 mg, once daily, compared to adalimumab (HUMIRA®) 40 mg, every other week, in adult patients with moderate to severe rheumatoid arthritis (RA) on a stable background of methotrexate (MTX) who had an inadequate response or intolerance to a TNF inhibitor (TNFi) other than adalimumab.1 This study achieved the primary endpoint and the majority of ranked secondary endpoints at week 12 with no new safety risks identified.1 The manuscript of the study is available on Annals of the Rheumatic Diseases.","length":719,"tagName":"p"},{"type":"image","alt":"RINVOQ® (CNW Group/AbbVie Canada) (CNW Group/AbbVie Canada)","displaySize":"","headline":null,"caption":"RINVOQ® (CNW Group/AbbVie Canada) (CNW Group/AbbVie Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/cnwgroup.com/f8170aa47e3a2231ddd3b94de64152f3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XVxdXzTFZFhiNAnNpAHZRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5Nw--/https://media.zenfs.com/en/cnwgroup.com/f8170aa47e3a2231ddd3b94de64152f3","width":400,"height":225}},"href":"https...